Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.
Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Research Hospital IRCCS, 20089 Milan, Italy.
Viruses. 2023 Aug 14;15(8):1738. doi: 10.3390/v15081738.
Ursodeoxycholic acid (UDCA) was demonstrated to reduce susceptibility to SARS-CoV-2 infection in vitro and improve infection course in chronic liver diseases. However, real-life evidence is lacking. We analyzed the impact of UDCA on COVID-19 outcomes in patients hospitalized in a tertiary center. Between January 2020 and January 2023, among 3847 patients consecutively hospitalized for COVID19, 57 (=UDCA group) were taking UDCA. The UDCA and the control groups ( = 3790) did not differ concerning comorbidities including diabetes mellitus type 2 (15.8% vs. 12.8%) and neoplasia (12.3% vs. 9.4%). Liver diseases and vaccination rate were more common in the UDCA group (14.0% vs. 2.5% and 54.4% vs. 30.2%, respectively). Overall mortality and CPAP treatment were 22.8 % and 15.7% in the UDCA, and 21.3% and 25.9% in the control group. Mortality was similar ( = 0.243), whereas UDCA was associated with a lower rate of CPAP treatment (OR = 0.76, < 0.05). Treatment with UDCA was not an independent predictor of survival in patients hospitalized for COVID-19.
熊去氧胆酸 (UDCA) 已被证明可降低体外 SARS-CoV-2 感染的易感性，并改善慢性肝病患者的感染过程。然而，目前缺乏真实世界的证据。我们分析了 UDCA 对在三级中心住院的 COVID-19 患者结局的影响。在 2020 年 1 月至 2023 年 1 月期间，在连续因 COVID-19 住院的 3847 名患者中，有 57 名（UDCA 组）正在服用 UDCA。UDCA 组和对照组（=3790 名）在包括 2 型糖尿病（15.8% vs. 12.8%）和肿瘤（12.3% vs. 9.4%）在内的合并症方面没有差异。UDCA 组的肝脏疾病和疫苗接种率更高（14.0% vs. 2.5%和 54.4% vs. 30.2%）。在 UDCA 组中，总体死亡率和 CPAP 治疗分别为 22.8%和 15.7%，而对照组分别为 21.3%和 25.9%。死亡率相似（=0.243），但 UDCA 与 CPAP 治疗率较低相关（OR=0.76，<0.05）。在 COVID-19 住院患者中，UDCA 治疗不是生存的独立预测因素。
Zotero 插件